stoxline Quote Chart Rank Option Currency Glossary
Checkpoint Therapeutics, Inc. (CKPT)
3.29  0.06 (1.86%)    12-08 16:00
Open: 3.26
High: 3.34
Volume: 781,374
Pre. Close: 3.23
Low: 3.06
Market Cap: 79(M)
Technical analysis
2023-12-08 4:42:21 PM
Short term     
Mid term     
Targets 6-month :  4.22 1-year :  4.93
Resists First :  3.61 Second :  4.22
Pivot price 2.57
Supports First :  2.42 Second :  1.67
MAs MA(5) :  3.11 MA(20) :  2.39
MA(100) :  2.13 MA(250) :  3.13
MACD MACD :  0.3 Signal :  0.2
%K %D K(14,3) :  82.6 D(3) :  87.5
RSI RSI(14): 84
52-week High :  8.14 Low :  1.29
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CKPT ] has closed below upper band by 10.0%. Bollinger Bands are 140.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.34 - 3.36 3.36 - 3.37
Low: 3.03 - 3.04 3.04 - 3.05
Close: 3.26 - 3.29 3.29 - 3.31
Company Description

Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Headline News

Thu, 07 Dec 2023
Where Does Checkpoint Therapeutics Inc (CKPT) Stock Fall in the Biotechnology Field After It Is Up 33.08% This Week? - InvestorsObserver

Wed, 06 Dec 2023
Is Checkpoint Therapeutics Inc (CKPT) Stock Worth a Buy Wednesday? - InvestorsObserver

Tue, 05 Dec 2023
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance - Yahoo Finance

Fri, 01 Dec 2023
Do Traders Think Checkpoint Therapeutics Inc (CKPT) Can Keep Climbing Friday? - InvestorsObserver

Thu, 30 Nov 2023
Should You Add Checkpoint Therapeutics Inc (CKPT) Stock to Your Portfolio Thursday? - InvestorsObserver

Mon, 13 Nov 2023
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 23 (M)
Held by Insiders 1.835e+007 (%)
Held by Institutions 16.1 (%)
Shares Short 2,160 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -24 %
Return on Assets (ttm) 841.9 %
Return on Equity (ttm) -307.4 %
Qtrly Rev. Growth 171000 %
Gross Profit (p.s.) -26.62
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -4.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -56 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -5.15
Stock Dividends
Dividend 0
Forward Dividend 2.65e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android